Abstract

Dysregulated post-translational modification provides a source of altered self-antigens that can stimulate immune responses in autoimmunity, inflammation, and cancer. In recent years, phosphorylated peptides have emerged as a group of tumour-associated antigens presented by MHC molecules and recognised by T cells, and represent promising candidates for cancer immunotherapy. However, the impact of phosphorylation on the antigenic identity of phosphopeptide epitopes is unclear. Here we examined this by determining structures of MHC-bound phosphopeptides bearing canonical position 4-phosphorylations in the presence and absence of their phosphate moiety, and examining phosphopeptide recognition by the T cell receptor (TCR). Strikingly, two peptides exhibited major conformational changes upon phosphorylation, involving a similar molecular mechanism, which focussed changes on the central peptide region most critical for T cell recognition. In contrast, a third epitope displayed little conformational alteration upon phosphorylation. In addition, binding studies demonstrated TCR interaction with an MHC-bound phosphopeptide was both epitope-specific and absolutely dependent upon phosphorylation status. These results highlight the critical influence of phosphorylation on the antigenic identity of naturally processed class I MHC epitopes. In doing so they provide a molecular framework for understanding phosphopeptide-specific immune responses, and have implications for the development of phosphopeptide antigen-specific cancer immunotherapy approaches.

Highlights

  • MHC-restricted phosphopeptides represent promising tumour-associated antigens for cancer immunotherapy

  • Our results suggest phosphorylation can exert a critical influence on both epitope conformation and T cell receptor (TCR)/ pMHC binding, and highlight the possibility of targeting specific tumour associated phosphopeptides for cancer immunotherapy

  • We observed well-defined electron density for each peptide moiety (Figure 2). These antigens are attractive therapeutic targets, as PKD2 is dysregulated in several solid tumours, implicated in the transformation process, and a target for chemotherapy [16]; Lymphocyte Specific Protein 1 (LSP-1) is a marker of lymphoma [17], and the RQA_V epitope is elevated on the surface of a range of tumour cell lines and primary leukemic tissue [11]; adenosine monophosphate deaminase 2 (AMPD2) expression has been noted on both melanoma www.impactjournals.com/oncotarget www.impactjournals.com/oncotarget and ovarian carcinoma cell lines [5]

Read more

Summary

Introduction

MHC-restricted phosphopeptides represent promising tumour-associated antigens for cancer immunotherapy. Phosphopeptide antigens are naturally processed and presented on human tumour cells by class I and class II MHC molecules [1,2,3,4,5]. The source proteins for phosphopeptide antigens include those involved in cytoplasmic signalling pathways, metabolism, or cell cycle regulation, many of which are implicated in cellular transformation [1, 4, 5]. Consistent with this, we recently identified numerous phosphopeptide antigens selectively presented on primary haematological malignancies, many of which were immunogenic and might contribute to tumour immunosurveillance [11]. These factors suggest phosphopeptide antigens may provide functionally important targets for cancer immunotherapy

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call